The company’s global head of cancer research Norbert Kraut added that “around one-third of the new products at Boehringer ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

–(BUSINESS WIRE)–October 9, 2024– Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal to develop a first-in-class ...

Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new precision cancer treatment. The partnership aims to create a first-in-class ...